The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| NEUROPACE INC | COM | 641288105 | 26,081,955 | 5,621,111 | SH | SOLE | 5,621,111 | 0 | 0 | |||
| SIGHT SCIENCES INC | COM | 82657M105 | 41,214,012 | 4,715,562 | SH | SOLE | 4,715,562 | 0 | 0 | |||
| AILERON THERAPEUTICS INC | COM NEW | 00887A204 | 27,703 | 22,341 | SH | SOLE | 22,341 | 0 | 0 | |||